Chemotherapy-free treatment shows promise for some patients with metastatic breast cancer
Researchers at the Icahn School of Medicine at Mount Sinai found that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with HR-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some patients and avoids chemotherapy.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a promising chemotherapy-free treatment option for patients with HR-positive, HER2-positive metastatic breast cancer. The four-drug combination - anastrozole, palbociclib, trastuzumab, and pertuzumab - exhibited encouraging results in a phase 1/2 ASPIRE clinical trial, potentially offering a more convenient and less burdensome alternative to traditional chemotherapy.
Published in the Journal of the National Cancer Institute, these findings were observed in 29 patients who demonstrated a 97% clinical benefit during the first six months of treatment, with a median progression-free survival of nearly 25 months. While these results warrant further investigation in larger randomized trials, they suggest that some patients may benefit from this targeted therapy regimen as a first-line treatment.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
